Kornimate/medical-research-clean huggingface dataset:
sphenopalatine ganglion blocks rct

Conditions: Migraine

Summary: rct of sphenopalatine ganglion (spg) blocks using anesthetics vs. placebo for migraine.

chronic migraine is a brain disorder with high prevalence. it is the 7th leading cause of disability worldwide according the who. spg block is a treatment for migraine that has been used for two decades. it can be done by needle injection of anesthetic to the region of the spg. however, there are now multiple catheter devices that can be used to non-invasively administer anesthetic topically through the nasal cavity to the region of the spg where the anesthetic is then absorbed through thin membranes covering the spg. various anesthetic agents have been studied however currently, to our knowledge, there is no head to head comparison of the various anesthetics used. studies of spg blocks in the setting of chronic migraine are few as compared to the use of spg as acute treatment for migraine. with the use of an rct, we aim to determine the overall efficacy of spg blocks used at longer intervals than have been studied in the past as compared to placebo, as well as to examine the relative efficacy of the anesthetics used most commonly and studied for spg blocks. we will be using an fda cleared device, the sphenocath which was developed and registered with the fda for this specific population and purpose. the study intervention is the standard practice in the ucsf headache center to perform spg blocks for our patients with chronic migraine. the frequency we use in clinical practice and that we plan to study is less often than in previous studies of this intervention in this population.

Eligibility criteria:
inclusion criteria: 1. age 18 years or more at time of consent 2. current patients in the ucsf headache center eligible to receive spg blocks for migraine and would otherwise receive treatment clinically 3. ability to provide consent for the research study exclusion criteria 1. pregnant or breast feeding within 4 weeks of enrollment 2. inability to communicate with the study team 3. patients who cannot read and understand english 4. deemed unsuitable for enrollment in study by the investigator 5. allergy to local anesthetics or saline
study of produce prescription programs in adults with overweight or obesity experiencing nutrition insecurity

Conditions: Overweight and Obesity

Summary: the goal of this study is to understand the best practices for implementing produce prescriptions among adults with overweight or obesity experiencing nutrition insecurity. enrolled participants will receive an 8-week intervention aimed at increasing nutrition knowledge, self-efficacy for healthy eating, and barriers to healthy food access. participants will be randomly assigned to one of two produce prescription implementation strategies: program 1: participants will receive weekly produce vouchers that are redeemable at a local vendor. program 2. participants will receive fresh produce delivered directly to the participant's home. these boxes will be tailored based on household size, cooking and preparation preferences, and produce the participant prefers to receive. researchers will compare engagement in and adherence to the intervention and the patterns of difference in 8-week changes in fruit and vegetable consumption and weight.


Eligibility criteria:
inclusion criteria: * adult 18 years of age or older * living with overweight or obesity, defined as a bmi ≥25 * screens positive for nutrition insecurity * has a smartphone with a data plan * willing to receive daily text messages * has an address that can receive delivery * can read and write in english * is willing to pick up produce at the northeast market exclusion criteria: * participating in another related research study * currently taking weight loss drugs * cardiovascular disease event in the last 6 months * active cancer * recent hospitalization due to psychiatric condition or event * pregnancy or planned during the study period * currently breastfeeding * documented dementia * on kidney dialysis * planned or recent bariatric surgery * weight exceeding 440 lbs. * exclusion at principal investigators discretion

Keywords: obesity overweight produce prescription produce voucher nutrition nutrition security
arm boot camp study: evaluation of a program to increase upper limb recovery after stroke

Conditions: Stroke; Cerebral Infarction; Brain Diseases; Central Nervous System Diseases; Cerebrovascular Disorders; Brain Ischemia; Brain Infarction; Vascular Diseases; Infarction; Nervous System Diseases; Cardiovascular Diseases

Summary: this study will examine the feasibility and effect of a program that combines exercise and feedback from a wearable device on upper limb movement practice and function in individuals with stroke.

participants will be randomized into either the immediate treatment group or the delayed treatment group. both groups will complete the same intervention program. the immediate treatment group will start the program right away while the delayed treatment group will start the program after a 3 week delay. the intervention program is 3 weeks in duration and consists of participants completing at least two hours of exercises (adapted from the home-grasp program) daily and wearing an activity monitor on their affected wrist during waking hours for the duration of the intervention. participants will be asked to meet daily movement count goals based on information from the monitor. participants will have 6 virtual sessions with a therapist who will teach and monitor exercises thru an online platform (zoom video communications), work with participants to generate and progress daily movement goals and discuss barriers and potential solutions to exercise adherence and/or meeting movement goals.

Eligibility criteria:
inclusion criteria: * 19 years or older * \< 1 year since the stroke occurred * living in the community * have unilateral upper limb impairment * have some ability to move their arm and hand (\> 30° shoulder flexion or abduction and fugl meyer finger extension score \> 0) * are using their affected upper limb in a different way than prior to their stroke (reach score \< 4) * completed formal physical and occupational therapy rehabilitation for the upper limb * have access to a tablet, computer, laptop or phone with internet and email access. note: if participant have a caregiver, we would like to invite him/her to assist in this study; however, a caregiver is not a must for participating in this study. exclusion criteria: * musculoskeletal/other neurological conditions that limit movement in their arm * unable to provide informed consent * have another medical condition that would affect their ability to participate in the treatment protocol * have persistent pain in their affected upper limb that affects their ability to use the limb * unable to speak, understand, or read english (unless another person, \[i.e., family member, care taker or friend\] can be present and translate during measurement/treatment sessions, and home activities related to the study

Keywords: stroke upper extremity rehabilitation wearable device exercise randomized controlled trial
comparing the performance of 1 day multifocal contact lenses

Conditions: Presbyopia

Summary: the objective of the study was to compare the lens handling and performance of lens a to habitually worn multifocal contact lenses and to the competitor lens b.

the objective of the study was to compare the lens handling and performance of lens a to habitually worn multifocal contact lenses and to the competitor lens b. this was a prospective, randomized, participant-masked, crossover, bilateral dispensing study conducted at up to 5 clinical practice sites in the united states. subjects were dispensed their habitual lenses for two weeks prior to randomization of test lens and control lens. each lens type will be worn for 2 weeks after randomization.

Eligibility criteria:
inclusion criteria: 1. is at least 42 years of age and has full legal capacity to volunteer; 2. has read and signed an information consent letter; 3. self reports having a full eye examination in the previous two years; 4. anticipates being able to wear the study lenses for at least 8 hours a day, 5 days a week; 5. is willing and able to follow instructions and maintain the appointment schedule; 6. habitually wears multifocal soft contact lenses, for the past 3 months minimum; 7. has refractive astigmatism no higher than -0.75dc; 8. is presbyopic and requires a reading addition of at least +0.75d and no more than +2.50d; 9. can be fit and achieve binocular distance vision of at least 20/30 snellen (or +0.20 logmar) which participants also deem to be 'acceptable', with the available study lens parameters (sphere +4 to -6; near addition or low, medium, high). exclusion criteria: 1. is participating in any concurrent clinical or research study; 2. habitually wears one of the study contact lenses; 3. has any known active\* ocular disease and/or infection that contraindicates contact lens wear; 4. has a systemic condition that in the opinion of the investigator may affect a study outcome variable; 5. is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable; 6. has known sensitivity to the diagnostic sodium fluorescein used in the study; 7. self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment; 8. has undergone refractive error surgery or intraocular surgery.
analgesic effect of ropivacaine plus fentanyl vs ropivacaine for continuous 3-in-1 fnb after total knee arthroplasty

Conditions: Pain

Summary: the postoperative analgesic effect of the continuous 3-in-1 femoral nerve block (fnb) with ropivacaine/fentanyl or with ropivacaine were compared in total knee arthroplasty.

forty patients of american society of anesthesiologist physical status ⅰor ⅱ undergoing total knee arthroplasty under spinal anesthesia would be enrolled and randomly divided into two groups (r, "3-in-1" using a 30 ml of ropivacaine 0.375% and a continuous 3-in-1 with a ropivacaine 0.2%(8ml/h) for 48 h after operation, rf: fifty ug of fentanyl will be added to a bolus(30ml ropivacaine 0.375%) and 1ug/ml of fentanyl will be mixed to a continuous infusion(8mg/h, ropivacaine 0.2%). spinal anesthesia will be done after the insertion of femoral catheter. iv pca with hydromorphone(0.15mg/ml, 0-1-10), will be used for rescue analgesics. visual analgesia scale, hydromorphone consumption, side effects until 48h after operation and satisfaction will be compared.

Eligibility criteria:
inclusion criteria: * asa ps 1 to 3 undergoing total knee arthroplasty under spinal anesthesia exclusion criteria: * patients were excluded from this study if they had contraindications to a regional anesthetic technique (e. g., local infection, sepsis, coagulation abnormality), allergy to local anesthetic or fentanyl, preexisting neurologic deficit in the lower extremities, and inability to comprehend the pain scales or use iv patient-controlled analgesia (pca) device.
safety and efficacy of recombinant adeno-associated virus containing the cftr gene in the treatment of cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to confirm the improvement in pulmonary function and cytokine levels observed in the recently completed multidose aerosol study for the treatment of cystic fibrosis (cf).

cystic fibrosis is an autosomal recessive disorder with an incidence of approximately 1 in 33000 live births. it is due to defects in the cftr gene, which is located on chromosome 7. gene therapy holds the promise of addressing the primary defect in cf by reconstituting the cftr function in the lung. tgaavcf, which has been genetically engineered to contain the cftr gene, has been extremely well tolerated following single and multiple dose administrations to the nose, sinus, and lung. dose-dependent gene transfer has been demonstrated. although vector gene expression has not been detected, evidence consistent with biological activity was observed in maxillary sinus study, and statistically significant changes in the fev1 and il-8 levels were observed in the recently completed multidose aerosol study. these findings are worthy of further investigation.

Eligibility criteria:
eligible subjects will be randomized to two aerosolized doses of either tgaavcf or placebo 30 days apart. subjects will undergo pulmonary function testing every two weeks during the active portion of the study (three months) and will be followed for safety for a total of seven months.

Keywords: gene transfer pulmonary function
the effect of transcutaneous electrical nerve stimulation on pain during venous cannulation

Conditions: Cannulation Pain

Summary: the purpose of this study was to investigate whether transcutaneous electrical nerve stimulation (tens) could reduce pain during cannulation of vein.

one hundred patients were allocated randomly to two groups: in the active tens group tens was delivered via two electrodes on the venous cannulation site (radial side of the wrist of dominant forearm) 20 min prior to venous cannulation and control group received placebo (no current) tens. venous cannulation with a 22 gage cannula was performed. during venous cannulation the pain intensity (0 = no pain, 10 = worst pain imaginable) was measured. any side effects during study periods were recorded

Eligibility criteria:
inclusion criteria: * outpatients who underwent plastic surgery exclusion criteria: * concomitant sedative or analgesic medication, * neurological disease. * all patients with potentially dangerous internal diseases (american society of anesthesiologists' physical status \> 3).

Keywords: pain transcutaneous electrical nerve stimulation
contrast-enhanced ultrasound in human crohn's disease

Conditions: Crohn's Disease

Summary: to determine if contrast enhanced ultrasound (ceus) and shear wave elastography can accurately diagnose bowel wall inflammation and fibrosis in patients with known crohn's disease.

crohn's disease (cd) is an inflammatory condition that affects the intestinal tract (large and small bowels). some patients with cd may get swelling of the intestinal tract (inflammation) or scarring of the intestinal tract (fibrosis). fibrosis develops because of chronic injury. both inflammation (swelling) and fibrosis (scarring) can cause the bowel to narrow, which can lead to the bowel becoming blocked. the long-term goal of this project is to develop new noninvasive radiology imaging tests that can show the difference between bowel wall inflammation and fibrosis. currently there are no imaging tests that can do this reliably. current imaging methods (ct and mri) that are ordered to help diagnose and follow-up cd are excellent at showing inflammation, but are not accurate for finding fibrosis. ct also exposes patients to small amounts of radiation, and both ct and mri are costly. we are therefore studying ultrasound imaging, as it is more cost-effective and does not expose patients to radiation. ceus uses microbubbles in a solution that are injected into a vein in one of the arms. this allows doctors to see the blood flow to parts of the body. this microbubble contrast agent (dye) is called optison. another imaging method, called shear wave elastography, uses sound waves to noninvasively measure the stiffness of structures in the body. it is important to be able to tell the difference between inflammation and fibrosis in crohn's disease, because narrowing of the bowel due to inflammation generally responds well to medications, whereas narrowing caused by fibrosis does not respond well to medications and may require surgery.

Eligibility criteria:
inclusion criteria: * patients 10 years of age and older * have been diagnosed with small bowel crohn's disease * are receiving medical therapy for crohn's disease * are scheduled for surgery (bowel resection) or * are scheduled for a clinically-indicated mr enterography (mre)/mri exam. exclusion criteria: * patients under the age of 10 * are pregnant or breast feeding * are significantly overweight - bmi \>35-40 * have an inability to understand the consent * have prior allergic-like reaction or other adverse reaction to microbubble contrast agent * hypersensitivity to perflutren, blood, blood products or albumen * have a cardiac shunt * known unstable cardiac condition such as history of a heart attach, irregular heartbeat, congestive heart failure, etc. * known acute or chronic kidney disease, moderate/severe lung disease or acute or chronic liver disease
long-term follow-up after stroke (the last-long trial)

Conditions: Stroke

Summary: despite the improved treatment of acute stroke over the past decades, those suffering from stroke still are at an increased risk of functional and cognitive decline in the long term. the most common consequences of stroke are functional impairments, cognitive impairments, depression and fatigue. these are also regarded as barriers to achieve optimal adherence to the guidelines regarding secondary prevention. the primary aim of this project is to evaluate the effectiveness of a multimodal individualized intervention to prevent functional decline in the long term after stroke.

in a clinical randomized controlled trial, participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months. the stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up. those randomized to the control group will receive standard care. patients living in the municipalities of trondheim, lørenskog and skedsmo admitted to akershus university hospital or st. olavs university hospital will be included at the outpatients clinic 3 months after the stroke. all patients will be re-assessed at 6, 12 and 18 months after inclusion. primary outcome will be modified rankin scale at 18 months.

Eligibility criteria:
inclusion criteria: * diagnosis of first ever or recurrent stroke (ischemic stroke or hemorrhage) * mrs \< 5 * living in trondheim, skedsmo or lørenskog municipality * less than 10 points on short physical performance battery (sppb) or less than 26 points on montreal cognitive assessment (moca) or more than 27 points on the 7 item version of the fatigue severity scale (fss-7) or more than 7 points on the depression or anxiety items on hospital anxiety and depression scale (hads) or reduced hand function (i.e. fails on motor assessment scale - advanced arm- and hand function, item 3) * able to understand norwegian * able and willing to sign informed consent. exclusion criteria: * life expectancy \< 12 months * other serious diseases, judged by the medical doctor to make it difficult to comply with the intervention (i.e. serious neurological diseases or drug abuse).

Keywords: rehabilitation cognition physical fitness case managers secondary prevention
unrelated donor stem cell transplantation

Conditions: Severe Aplastic Anemia; Paroxysmal Nocturnal Hemoglobinuria; Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Myeloproliferative Syndromes; Chronic Myelogenous Leukemia; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Large Granulocytic Leukemia

Summary: the purpose of this study is to provide an opportunity for patients with malignancies or bone marrow failure states who lack a suitable sibling donor to undergo allogeneic hematopoietic progenitor cell transplantation using cells from unrelated individuals or cord blood registries.

same

Eligibility criteria:
inclusion criteria: * \> 18 years of age * \< 70 years * ecog performance status 0, 1 or 2 * left ventricular ejection fraction \> 30% * creatinine clearance \> 40ml/min * transaminases \< 2x normal * total bilirubin \< 2x normal * hiv seronegativity * weight \< 70kg for cord blood transplantation * ability to cover the cost of the transplant, necessary medications, and transportation/housing. * caregiver must be available while outpatient exclusion criteria: * greater than one antigen mismatch at hla-a, b, c or dr plus one allele mismatch at hla-a, b, c or dr

Keywords: transplant allogeneic allogeneic transplant unrelated donor transplant mud hsct stem cell transplant
referral training and egen trials

Conditions: Behavioral Problem; Behavioral Problem of Child

Summary: child and adolescent behavioral health problems are related to the leading causes of youth morbidity and mortality. parent-focused interventions effectively prevent behavioral health problems such as depression and conduct disorders and can provide a downstream economic benefit to society by reducing criminal activity, education costs, and health care use. unfortunately, parenting programs are not widely available, accessible, nor well-attended. pediatric primary care is a non-stigmatizing setting with nearly universal reach and, therefore, an ideal contact point to increase access. however, primary care clinicians (pccs) often have insufficient training in behavioral health topics and typical referral practices are inadequate. there are also logistical barriers to attending in-person parenting programs, like the need for childcare and a large time-commitment. there is a need to develop effective referral practices in conjunction with increasing the accessibility of parenting programs. the study long-term goal is to prevent significant behavioral health problems through widespread access to effective and accessible parenting programs through primary care referrals. in this study there are two trials: first is the primary care clinicians "pcc" trial, testing the effectiveness of referral training (aim 1). second is the parents "egen" trial provided by therapists, testing the effectiveness of egen parenting intervention (aim 2).


Eligibility criteria:
inclusion criteria: * inclusion criteria for parent in the randomized controlled trial include being a parent or caregiver of a child ages 3 to 8 and having a referral to a participating therapist from a primary care provider. * the only inclusion criteria is that participants be a pcc who sees children between the ages of 3- 8 years old. pccs must also have approval from their clinic to participate. vulnerable populations will not be targeted from inclusion but may be included if they meet the previously stated inclusion criteria. exclusion criteria: * parents would be excluded if there is a reasonable belief that participating could increase danger to a child or if they are psychologically unable to engage in the intervention activities.